BioMedNewsBreaks

ThursdayMar 07, 2024 1:09 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). An archived version of the presentation will be available following the webcast on the company website.…

Continue Reading

TuesdayMar 05, 2024 3:07 pm

BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy…

Continue Reading

TuesdayMar 05, 2024 2:43 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, March 20, 2024, HeartBeam executives will also provide regulatory updates, reviewing ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno, Consulting CFO Richard Brounstein, and VP of Regulatory Affairs Deborah Castillo, PhD, will host the call, followed by…

Continue Reading

TuesdayMar 05, 2024 1:54 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North America. Represented by its senior research and clinical development team and co-authored by several of its esteemed scientific advisors, FSD shared the results of its phase 1 clinical study. The results were displayed in a…

Continue Reading

MondayMar 04, 2024 2:35 pm

BioMedNewsBreaks – BioVie Inc. (NASDAQ: BIVI) to Secure ~$21M in Public Offering

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. The company today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or pre-funded warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable for a period of five years following the date…

Continue Reading

MondayMar 04, 2024 2:24 pm

BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Closes on Private Placement Valued at Up to $16M

Biofrontera (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, has closed on a securities purchase agreement. According to the announcement, the agreement is with healthcare-focused institutional investors led by Rosalind Advisors. The financing is for an initial $8 million with an additional $8 million second tranche, dependent on the company reaching specified milestones. The company noted that the funding, along with recent restructuring of a supply agreement, allow it to conduct planned research and development activities as well as support further commercial growth. “The company intends to use the upfront net proceeds from the private placement…

Continue Reading

FridayMar 01, 2024 3:40 pm

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other secured points around the world. It is powered by the Astrotech Mass Spectrometer (‘AMS’) Technology that is inexpensive, smaller and easier to use when compared to traditional mass spectrometers. The AMS Technology works under ultra-high…

Continue Reading

FridayMar 01, 2024 3:12 pm

BioMedNewsBreaks — Astiva Health Redefining the Standards of Personalized and Comprehensive Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, is one of the companies committed to providing robust and stable benefit offerings to a growing number of people looking for the best Medicare options. “In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (‘MAPD’) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success, Astiva recently reached a key milestone, surpassing the 10,000-member mark… Reaching the milestone –…

Continue Reading

FridayMar 01, 2024 2:03 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (‘CDC’). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the treatment available on the market addresses symptoms of the…

Continue Reading

ThursdayFeb 29, 2024 10:18 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented the results at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in Florida. The results were gathered from the VISIONARY-MS trial long-term open label extension (“LTE”) in participants with stable…

Continue Reading